Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
Sponsor: Kiminori Kimura, MD
Summary
This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.
Official title: A Multicenter, Single-Arm, Open-Label Phase 2 Study of Once-Weekly Foscenvivint in Patients With Liver Cirrhosis Due to HIV/HCV Co-infection in the Setting of Hemophilia
Key Details
Gender
MALE
Age Range
18 Years - 79 Years
Study Type
INTERVENTIONAL
Enrollment
4
Start Date
2026-09-01
Completion Date
2028-03-31
Last Updated
2026-08-05
Healthy Volunteers
No
Conditions
Interventions
Foscenvivint
Experimental:Foscenvivint Administered by intravenous (IV) infusion over 3-4 hours Arm Description:Foscenvivint 280 mg/m2, once a week for 24 weeks
Locations (3)
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
National Hospital Organization Osaka National Hospital
Osaka, Osaka, Japan
Tokyo Metropolitan Komagome Hospital
Bunkyo-Ku, Tokyo, Japan